A Phase 1 interventional study of Arm 1: Radix Puerariae lobatae (Gegen) and Arm 1: Six-probe drug cocktail in Herb-drug Interactions, sponsored by Chinese University of Hong Kong. Completed at 1 site in Hong Kong. Open to participants aged 20 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by Chinese University of Hong Kong · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Purpose:
The purpose of this study is to understand how the traditional herbal medicine kudzu root (Gegen, Radix Puerariae lobatae) affects the activity of drug metabolizing enzymes in the body, and whether this could lead to interactions with other medicines.
Background:
Many medicines are broken down in the body by enzymes called cytochrome P450 (CYP) enzymes. Preclinical data suggest that Gegen can inhibit CYP enzymes, which may lead to herb-drug interactions; however, robust clinical evidence in humans remains insufficient.
Participants:
This study recruited 56 healthy Chinese adults, who were randomly assigned to parallel low and high dose Gegen groups; 52 participants finished the study.
Interventions:
Participants took a mixture of probe medicines known as a CYP probe cocktail to measure baseline CYP enzyme activity. After receiving either low or high dose Gegen, they received the probe cocktail again to detect changes in enzyme activity. Blood samples were collected to test the probe medicines, their breakdown products, and markers for blood clotting and blood vessel health.
Outcome Measures:
Primary outcomes include changes in blood levels and metabolic ratios of probe medicines. These values reflect differences in CYP enzyme activity with and without Gegen, and are compared across low and high dose groups.
Hypothesis:
The study hypothesized that Gegen alters CYP enzyme activity, and that the magnitude of this effect varies with Gegen dose.
Gegen (Radix Puerariae lobatae) is a common traditional Chinese herbal medicine. Preclinical data indicate its potential to inhibit cytochrome P450 enzymes, which may lead to herb-drug interactions. However, robust clinical evidence in humans remains insufficient.This randomized, two-period study enrolled healthy Chinese adults, with participants allocated to parallel low-dose and high-dose Gegen groups. A six-probe drug cocktail was administered before and after Gegen intake to characterize in vivo CYP enzyme activity under intervention and control conditions.Serial blood samples were collected to quantify probe substrates and metabolites for CYP phenotyping, and to measure circulating biomarkers of coagulation and endothelial function for safety assessment. This study evaluated Gegen's effects on six key human CYP isoforms (CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A). Enzyme activity was assessed using metabolic ratios and AUC-based drug exposure comparisons. Specific coagulation and endothelial biomarkers, including thromboxane B2 and soluble thrombomodulin, were examined. Adverse events were monitored throughout the study.The results of this study provide insight into the isoform-specific modulation of CYP enzymes by Gegen and its potential implications for herb-drug interactions involving CYP-metabolized medications.
Chinese University of Hong Kong is the lead sponsor of 1,455 studies on the registry; 475 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Oct 5, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received the low-dose (3.3 g) Gegen regimen for 14 days; the six-probe drug cocktail was administered once before (Session I, baseline) and once after (Session II) Gegen dosing for CYP phenotyping.
Drug: Arm 1: Radix Puerariae lobatae (Gegen) · Drug: Arm 1: Six-probe drug cocktail
Participants received the high-dose (5 g) Gegen regimen for 14 days; the six-probe drug cocktail was administered once before (Session I, baseline) and once after (Session II) Gegen dosing for CYP phenotyping.
Drug: Arm 2: Radix Puerariae lobatae (Gegen) · Drug: Arm 2: Six-probe drug cocktail
Granules of the dried root of Pueraria lobata (listed in the Hong Kong Chinese Materia Medica Standards; Chinese Pharmacopoeia monograph Radix Puerariae Lobatae).
Also known as: Puerariae Lobatae Radix, Kudzu Root, Lobed Kudzuvine Root
Single oral dose of a cocktail comprising caffeine (CYP1A2), efavirenz (CYP2B6), losartan (CYP2C9), omeprazole (CYP2C19), metoprolol (CYP2D6), and midazolam (CYP3A4).
Also known as: caffeine, efavirenz, losartan, omeprazole, metoprolol, midazolam
Granules of the dried root of Pueraria lobata (listed in the Hong Kong Chinese Materia Medica Standards; Chinese Pharmacopoeia monograph Radix Puerariae Lobatae).
Also known as: Puerariae Lobatae Radix, Kudzu Root, Lobed Kudzuvine Root
Single oral dose of a cocktail comprising caffeine (CYP1A2), efavirenz (CYP2B6), losartan (CYP2C9), omeprazole (CYP2C19), metoprolol (CYP2D6), and midazolam (CYP3A4).
Also known as: caffeine, efavirenz, losartan, omeprazole, metoprolol, midazolam
Change in CYP1A2 phenotypic activity
Plasma concentrations of caffeine and its metabolite paraxanthine were quantified by validated LC-MS/MS. CYP1A2 activity was expressed as the AUC0-t derived metabolite-to-parent ratio (unit of measure: ratio).
Time frame: Session I (baseline) and Session II (after 14 days of Gegen administration); within each session, blood samples were collected at pre-dose (0 hour) and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours after dosing of cocktail probe drugs.
Change in CYP2B6 phenotypic activity
Plasma concentrations of efavirenz and its metabolite 8-Hydroxy-efavirenz were quantified by validated LC-MS/MS. CYP1A2 activity was expressed as the AUC0-t derived metabolite-to-parent ratio (unit of measure: ratio).
Time frame: Session I (baseline) and Session II (after 14 days of Gegen administration); within each session, blood samples were collected at pre-dose (0 hour) and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours after dosing of cocktail probe drugs.
Change in CYP2C9 phenotypic activity
Plasma concentrations of losartan and its metabolite E-3174 were quantified by validated LC-MS/MS. CYP1A2 activity was expressed as the AUC0-t derived metabolite-to-parent ratio (unit of measure: ratio).
Time frame: Session I (baseline) and Session II (after 14 days of Gegen administration); within each session, blood samples were collected at pre-dose (0 hour) and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours after dosing of cocktail probe drugs.
Change in CYP2C19 phenotypic activity
Plasma concentrations of omeprazole and its metabolite 5-Hydroxy-omeprazole were quantified by validated LC-MS/MS. CYP1A2 activity was expressed as the AUC0-t derived metabolite-to-parent ratio (unit of measure: ratio).
Time frame: Session I (baseline) and Session II (after 14 days of Gegen administration); within each session, blood samples were collected at pre-dose (0 hour) and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours after dosing of cocktail probe drugs.
Change in CYP2D6 phenotypic activity
Plasma concentrations of metoprolol and its metabolite α-Hydroxy-metoprolol were quantified by validated LC-MS/MS. CYP1A2 activity was expressed as the AUC0-t derived metabolite-to-parent ratio (unit of measure: ratio).
Time frame: Session I (baseline) and Session II (after 14 days of Gegen administration); within each session, blood samples were collected at pre-dose (0 hour) and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours after dosing of cocktail probe drugs.
Change in CYP3A4 phenotypic activity
Plasma concentrations of midazolam and its metabolite 1'-Hydroxy-midazolam were quantified by validated LC-MS/MS. CYP1A2 activity was expressed as the AUC0-t derived metabolite-to-parent ratio (unit of measure: ratio).
Time frame: Session I (baseline) and Session II (after 14 days of Gegen administration); within each session, blood samples were collected at pre-dose (0 hour) and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 12, 24, 48, and 72 hours after dosing of cocktail probe drugs.
Change in thromboxane B2 concentration
Plasma concentration of thromboxane B2, a biomarker of platelet activation and coagulation, was quantified by enzyme-linked immunosorbent assay (unit of measure: ng/mL).
Time frame: Blood samples collected at pre-dose (0 hour) in Session I (baseline) and 72 hours post-cocktail-dose in Session II (after 14 days of Gegen dosing)
Change in soluble thrombomodulin concentration
Plasma concentration of soluble thrombomodulin, a biomarker of endothelial function, was quantified by enzyme-linked immunosorbent assay (unit of measure: ng/mL).
Time frame: Blood samples collected at pre-dose (0 hour) in Session I (baseline) and 72 hours post-cocktail-dose in Session II (after 14 days of Gegen dosing)
Change in prothrombin time
Plasma prothrombin time, a coagulation parameter, was measured by standard clotting assay on an automated coagulometer (unit of measure: seconds).
Time frame: Blood samples collected at pre-dose (0 hour) in Session I (baseline) and 72 hours post-cocktail-dose in Session II (after 14 days of Gegen dosing)
Incidence of adverse events
Number and percentage of participants with at least one adverse event, assessed by physical examination (general appearance, skin, head, eye, ear, nose, throat, neck, heart, chest, central neurologic system, abdomen, extremity), vital signs (body temperature, pulse, respirations, sitting systolic and diastolic pressures), 12-lead electrocardiogram (heart rate, PR interval, QRS duration, QT interval), and laboratory safety tests (haematology, blood chemistry, urinalysis).
Time frame: From enrolment until the final visit (72 hours after the Session II probe cocktail administration)
Plan to share: No — Dataset includes identifiable genotype information.
No publications or documents are linked to this record.
Ran from Aug 2022 to primary completion in Apr 2023, 8 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese University of Hong Kong →